Comparing rates of TE in patients with SCD using combined OCP based on estrogen dose and generation of progestin
| OCP formulation . | No. of users . | Rates of TE per 1000 person-y . | Unadjusted HR (95% CI) . | P . | Adjusted∗ HR (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Estrogen dose† | ||||||
| Ultra-low dose (<30 μg) | 1089 | 12.2 (6.8-22.0) | 0.71 (0.34-1.49) | .367 | 0.76 (0.36-1.60) | .472 |
| Low dose (30 to <50 μg) | 1425 | 17.1 (11.1-26.5) | Reference | — | Reference | — |
| Progestin generation‡ | ||||||
| Newer generation progestins | 1297 | 14.9 (9.1-24.4) | 1.03 (0.51-2.09) | .929 | 1.05 (0.52-2.13) | .895 |
| Other progestins | 1256 | 14.5 (8.7-24.0) | Reference | — | Reference | — |
| OCP formulation . | No. of users . | Rates of TE per 1000 person-y . | Unadjusted HR (95% CI) . | P . | Adjusted∗ HR (95% CI) . | P . |
|---|---|---|---|---|---|---|
| Estrogen dose† | ||||||
| Ultra-low dose (<30 μg) | 1089 | 12.2 (6.8-22.0) | 0.71 (0.34-1.49) | .367 | 0.76 (0.36-1.60) | .472 |
| Low dose (30 to <50 μg) | 1425 | 17.1 (11.1-26.5) | Reference | — | Reference | — |
| Progestin generation‡ | ||||||
| Newer generation progestins | 1297 | 14.9 (9.1-24.4) | 1.03 (0.51-2.09) | .929 | 1.05 (0.52-2.13) | .895 |
| Other progestins | 1256 | 14.5 (8.7-24.0) | Reference | — | Reference | — |
Adjusted for age group, SCD genotype, severity, and comorbidities of obesity, diabetes, hypertension, and cancer.
Analysis excluded patients receiving varying estrogen dose levels (n = 105) and patients receiving high-dose estrogen (n < 10).
Analysis excluded patients who were prescribed both types of progestin generations (n = 69).